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Abstract
Neurofibromatosis was first described in the nineteenth century. At the time, 
Friederich Daniel Von Recklinghausen detailed two cases of multiple neurofi-
bromas. Although reports of similar cases had been published before his, Von 
Recklinghausen is credited with the initial description in 1882, postulating that 
the tumors originated from nerve sheath and plexal connective tissue. Similarly, in 
1822 John Henry Wishart described what is believed to be neurofibromatosis type 
2; however, it was Harvey Cushing’s description of a case of bilateral vestibular 
schwannomas in 1916 that highlighted and increased awareness of the disease 
(albeit the original presentation was thought to be in the context of neurofibroma-
tosis type 1). Since their original description, understanding of these neurocutane-
ous diseases has greatly expanded. Knowledge of the genotypic mutations and 
molecular mechanisms underlying the disease pathophysiology has resulted in 
natural history enlightenment and optimal treatment refinement. However, many 
aspects of neurofibromatosis have yet to be explained and remain active areas of 
investigation. In this chapter, clinical, radiological, and surgical considerations for 
peripheral nerve tumor management in the context of neurocutaneous disorders 
are reviewed. More specifically, clinical presentations, pathological and imaging 
findings, as well as management for neurofibromatosis type 1, type 2, and  
schwannomatosis are comprehensively discussed.
Keywords: nerve sheath tumor, tumor, surgery, neurofibromatosis, 
schwannomatosis
1. Introduction
Neurocutaneous disorders are a group of diseases characterized by systemic 
structural abnormalities of tissues derived from the embryonic ectoderm. Among 
other manifestations, this results in the growth of peripheral nerve sheath tumors 
(PNSTs). More specifically, of the many diseases that fall under this category, neu-
rofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannoma-
tosis (SWNTS) are the three that predominate when considering those associated 
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with PNSTs. Furthermore, each of these three diseases has a specific gene that upon 
mutation results in different, albeit overlapping, clinical manifestations [1, 2].
Many different mutations have been linked to these diseases, which may then be 
inherited (familial forms) or occur sporadically. However, it is the specific geno-
typic mutation pattern of a patient that will then dictate and drive the molecular 
pathogenesis leading to their phenotypic disease expression [3, 4]. Because of this, 
each of the three diseases is generally associated with a particular type of periph-
eral nerve pathology, including benign PNST (BPNST, whether neurofibroma or 
schwannoma and the subcategories of each) and/or malignant PNST (MPNST). 
Moreover, each disease has unique epidemiological characteristics separating one 
from another. In this chapter, these characteristics, as well as each disease’s distinct 
clinical, radiological, and treatment-related challenges are discussed.
2. Neurofibromatosis type 1
2.1 Background
NF1 is the most common of the three neurocutaneous diseases with a reported 
incidence of 1:2500–3500 [5, 6]. It is characterized by a somatic or germ line muta-
tion on the long arm of chromosome 17 (ch17q11.2) and is inherited in an autosomal 
dominant (AD) fashion. This genetic locus codes for the protein neurofibromin and 
is a tumor suppressor gene expressed in multiple tissues. In short, neurofibromin 
is a GTPase-activating protein that catalyzes the inactivation of Ras protein (acting 
as a negative regulator in the Ras/MAPK signal transduction pathway) [6–8]. Its 
genetic alteration (via point mutations, deletions, insertions, microdeletions, and 
splicing mutations) results in a loss of inhibition of Ras that leads to hyperactiva-
tion of downstream effectors MEK, ERK, and/or mTOR [8]. The latter then results 
in Schwann cell proliferation and tumor growth. Although NF1 may be inherited in 
an AD fashion, approximately half of NF1 cases arise from de novo mutations. With 
more than 500 mutations identified to date, there are also many different types 
of mutations that can lead to NF1. Although the disease’s penetrance approaches 
100%, the expressivity of NF1 can be quite variable and may be dictated by the 
underlying genetic alterations [9]. For example, large complete gene deletions have 
been associated with intellectual disability, tumor burden, and their malignant 
transformation [10, 11]. More specifically, the predominant tumor burden that 
occurs in NF1 patients consists of neurofibromas. Neurofibromas are BPNSTs made 
up Schwann cells and/or perineurial cells, fibroblasts, hematopoietic cells, among 
others. After schwannomas, they are the most common type of PNST in the general 
population with a reported prevalence of 10–24% [12]. Unlike schwannomas, 
however, neurofibromas tend to be more widespread and occur in a slightly younger 
population (typically 20- to 30-year-olds) without a clear sex predilection [12–14]. 
Furthermore, they may occur sporadically or in the context of NF. Those occurring 
with NF tend to be numerous and, as will be discussed in the next section, of a 
 different histopathological category with a higher proclivity for malignancy.
2.2 Neurofibroma histopathology and subtypes
Neurofibromas are heterogeneous tumors believed to originate from Schwann 
cells [6, 15]. Grayish-tan in color, they are typically more fibrous and tenacious than 
schwannomas without necrosis or hemorrhage [16]. Microscopically, poorly orga-
nized spindle cells are seen within a myxoid tumor background of coarse collagen 
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bundles. Although somewhat variable, neurofibromas have low-to-moderate cel-
lularity with minimal mitoses compared to their malignant counterpart described 
below [7, 16].
Dermal (or cutaneous) neurofibromas are a type of neurofibromas with several 
subcategories. They are believed to arise from a single nerve and may be further 
subcategorized into localized or diffuse (90% and 10% of dermal neurofibromas, 
respectively) [10, 17]. Moreover, 90% of cutaneous neurofibromas occur sporadi-
cally, while the other 10% are syndromic [18, 19]. Although both are typically 
unencapsulated, localized neurofibromas are well circumscribed, whereas diffuse 
are an en-plaque-like growth and less delimited from surrounding tissue. Dermal 
neurofibromas do not usually require treatment (unless they are painful, bleeding, 
or interfere with an individual’s day-to-day function) [20], nor do they usually 
undergo malignant transformation [21].
Intraneural neurofibromas are localized, well-circumscribed BPNSTs arising 
as a fusiform enlargement of a single nerve. Localized intraneural neurofibromas 
may be seen as occurring cranially, spinally, peripherally, or from autonomic 
nerves; nerve is intermixed throughout the tumor [22]. Theses tumors are typi-
cally encapsulated and present as painful masses that can cause a sensorimotor 
neurologic deficit. Furthermore, they have an intermediate potential for malignant 
transformation [10].
Plexiform neurofibromas are complex lesions involving multiple nerve fascicles 
growing and coming together to make up an entangled neurofibromatous mass (“bag-
of-worms”). These occur almost exclusively in the context of NF1 (many considering 
them pathognomonic) and grow most rapidly during the first decade of life. The most 
common locations for this type of neurofibroma are paraspinal and plexal areas; how-
ever, they may also be seen peripherally (e.g., from the sciatic or femoral nerve) [23]. 
Overlying these tumors, cutaneous changes may be seen such as hyperpigmentation 
and thinning of hair. They are also associated with an increased risk of malignancy 
(MPNST) [17]. An increase in the size, progressive pain, and neurological deficit 
have all been found to be clinical indicators of malignant transformation and should 
prompt immediate diagnostic and/or therapeutic management.
Elephantiasis neurofibromatosa is a rare, massive, soft tissue tumor with an 
intermediate malignancy potential that is exclusive to NF1 (pathognomonic). It is 
the least frequent type of neurofibroma and consists of diffuse soft tissue enlarge-
ment (often in the extremities) with an underlying plexiform neurofibroma or 
enlarged nerve within the mass [10].
Atypical neurofibromas are simply neurofibromas (of any histological subtype, 
although certain types display a higher proclivity for atypical transformation) that 
display histopathological and molecular features involved in malignant transforma-
tion. However, they do not fit into a single grading system and more recently they 
have been termed “atypical neurofibromatous neoplasms of uncertain biological 
potential” (ANNUBP). These lesions may be destructive locally but are less likely to 
metastasize [21]. Even though atypia may be present, it is the loss of neurofibroma 
architecture, high cellularity, and presence of mitotic activity that are more associ-
ated with malignant transformation. ANNUBP has its own specific histological 
criteria for diagnosis; however, the inclusion of “uncertain” within its name argues 
the need for more research. For example, some tumors exhibit benign, atypical, 
and malignant features within the same lesion [17]. Furthermore, these lesions can 
be positive on fluorodeoxyglucose positron emission tomography (FDG-PET) and 
include areas of hypercellularity and atypical nuclei without increased mitotic activ-
ity or malignant change [24]. However, as in the case of MPNST suspicion, diagnosis 
of such a lesion should prompt more diagnostic and/or therapeutic intervention.
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Finally, hybrid neurofibromas are a histological class displaying characteristics 
of both schwannomas and neurofibromas. Approximately 60% of patients with 
these tumors carry a neurocutaneous diagnosis such as NF1, NF2, or SWNTS.
2.3 Malignant peripheral nerve sheath tumors
MPNSTs are aggressive sarcomas with a dismal prognosis arising from the 
peripheral nervous system (PNS) or peripheral nerve sheath cells. Grossly, they 
are typically fusiform or globoid in shape with a firm exterior and adherent to 
adjacent structures. Their center is often necrotic, with pseudocysts and evidence 
of hemorrhage. Microscopically, invasion into surrounding structures, vascular 
invasion, nuclear pleomorphism, increased cellularity, necrosis, and mitoses can 
be seen [9, 15, 16, 21].
They are graded according to the Enneking scheme and exist on a histological 
spectrum (low-grade, benign-like tumors on one end and high-grade, aggressive 
tumors with invasive and metastatic potential on the other) [15, 21]. Malignant 
transformation of BPNSTs in the context of NF1 patients is an area of active 
investigation. Akin to a two-hit hypothesis, mutation of the second neurofibromin 
encoding allele (or a second, intricately related gene) may be necessary for this 
transformation to occur [8, 10, 21, 25]. Approximately half of MPNSTs occur in the 
context of NF1 (one of the most important prognostic factors), and NF1 patients 
have approximately a 10% lifetime risk of acquiring this malignancy [26–28]. 
Of the subtypes, plexiform neurofibromas harbor the highest risk of malignant 
transformation with more than 80% of MPNSTs arising from them. These tend to 
occur between second and fifth decades of life (peak in third decade) [8, 11, 21] and 
typically occur at an earlier age in NF patients (second to third decade vs. third to 
sixth decade in the general population) [9]. Moreover, they are the most common 
type of malignancy in NF1 patients, as well as the most common cause of death 
[8]. In keeping with plexiform tumor characteristics, MPNSTs usually arise from 
large nerves or trunks (brachial and lumbosacral plexus or the sciatic nerve). They 
also often occur in a deep-to-fascial location (deep soft tissue and visceral tumors 
frequently being associated with NF1); however, they may occur more superficially 
as well [29]. As discussed in subsequent sections, MPNSTs are staged and treated as 
soft tissue sarcomas [8] with previous studies demonstrating a poor 5-year overall 
survival (OAS).
2.4 Clinical presentation
Neurofibromas are often an asymptomatic, incidental finding. However, when 
symptomatic, patients may experience pain, patchy anesthesia or paresthesia, and 
weakness [7]. The incidence of neurological deficit at presentation is higher for 
neurofibromas than schwannomas; furthermore, unlike sporadic cases, patients 
with NF1 can present with signs and symptoms from a multitude of different 
organ systems. Due to the ubiquitous and intricate nature of the Ras signal trans-
duction pathway, the effects of NF1 can be widespread (segmental neurofibro-
matosis being an exception) [30, 31]. Diagnosis of NF1 is based on the National 
Institutes of Health clinical consensus criteria (with optional genetic confirma-
tion), and the diagnosis of a neurofibroma (whether sporadic or syndromic, 
benign or malignant) is a histopathological one. However, the improvement in 
diagnostic accuracy of imaging investigations such as magnetic resonance imag-
ing (MRI) and PET has resulted in the necessity of biopsies being an antiquated 
notion. If required, the benefit of a biopsy should be weighed against risks such as 
neurological deficit and insufficient/non-diagnostic sampling error [9, 15, 17, 21].
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NF1 can present with cutaneous changes (café-au-lait spots and intertriginous 
freckling being reported in >99% and 85% of patients, respectively) [17], Lisch 
nodules (ocular hamartoma hyperpigmentations), skeletal abnormalities (long bone 
dysplasia and scoliosis), central nervous system (CNS) lesions such as optic nerve 
gliomas (15% of patients typically before 10 years of age), brainstem, and hemi-
spheric gliomas may also occur [6, 32, 33]. Moreover, unlike the other neurocutaneous 
syndromes, cognitive impairment (60% of patients) is also much more prevalent, 
as is non-nervous system involvement (leukemia, pheochromocytoma and glomus 
tumors, gastrointestinal tract tumors, and breast cancer) [6, 17, 32, 34, 35]. Patients 
with NF1 can also suffer from neurofibromatous neuropathy (a tumor independent, 
symmetrical sensory-motor neuropathy). This results in sensory predominant symp-
toms including pain and pruritus [4]. This neuropathy stems from a non-progressive 
and diffuse neurofibromatous nerve infiltration and hypertrophy. Although only 
affecting 2% of NF1 patients, it is associated with increased tumor burden and 
MPNST [4, 21].
2.5 Imaging
MRI is the preferred imaging modality for PNSTs [6, 15]. MR neurography 
can further determine whether a mass is intrinsic or extrinsic to the peripheral 
nerve and can aid in presurgical planning. In addition, whole body MRI can be 
used both for screening patients (quantifying initial tumor burden), as well as 
for tumor surveillance (to monitor for growth and/or malignant transformation) 
[36]. Signal intensity of neurofibromas is usually low on T1-weighted imaging 
and high on T2-weighted imaging (although large tumors can display peripheral, 
central or heterogeneous hyperintensity on T2 imaging). Enhancement can also be 
variable ranging from none to homogeneous. The classic pattern of enhancement 
with solitary neurofibromas is central enhancement surrounded by non-enhancing 
tissue. Isolated, non-plexiform neurofibromas appear as round or fusiform masses 
with tapering cranial and caudal ends due to continuity with the nerve. A sur-
rounding rim of intramuscular fat capping the edges of the lesion might give rise 
to the split-fat sign [23]. A target-sign (hyperintense ring of myxoid material with 
a hypointense center of collagen and fibrillary tissue) might also be present and is 
more commonly seen with neurofibromas than schwannomas [15, 23].
MPNSTs may arise from solitary or plexiform neurofibromas. MRI features sug-
gestive of MPNSTs include larger size (≥5 cm), peripheral enhancement, adjacent 
tissue invasion and peritumoral edema, vascular encasement, and metastases. 
MPNSTs are often irregularly shaped with heterogeneous enhancement, ill-defined 
margins, intra-tumoral lobulations, central necrosis and hemorrhage, absence  
of the target-sign, and an apparent diffusion coefficient (ADC) value of  
<1 × 10−3 mm2/s [8, 23, 37].
Functional imaging including PET may be helpful for the determination of 
malignancy, especially in atypical neurofibromas. A semi-quantitative assessment 
for the determination of malignancy can be done using a standard uptake value 
(SUV) cutoff [17]. While F-18-FDG PET activity is invariably present in both 
BPNSTs and MPSNTs, high SUVs favor the presence of malignancy. A SUV ≥4 is 
indicative of malignancy and can help direct the ideal site of biopsy [6, 8, 38].
Ultrasound (US) examination has also been shown to be helpful in the workup 
for neurofibromas. US findings may include hypoechoic lesions that are serpen-
tine, oval-shaped, and well-circumscribed with a fascicular pattern. Plexiform 
lesions can be multiloculated and nodular, whereas subcutaneous neurofibromas 
often have heterogeneous echogenicity with multifascicular involvement and a 
target-sign [35].
Neurofibromatosis - Current Trends and Future Directions
6
2.6 Management and outcome
Management of PNSTs is either surgical or expectant in nature (with the role 
of radiation and chemotherapy being reserved for select cases). Due to the diverse 
nature of neurofibromas with respect to subtypes and locations, a concise yet 
comprehensive description of surgical approaches is difficult. However, like other 
PNSTs, indications for surgical resection of a neurofibroma may include neurologi-
cal signs and symptoms referable to the lesion (pain, numbness, paresthesias, and 
weakness), growth demonstrated on serial imaging, questionable diagnosis or 
malignancy, and cosmesis.
Solitary, localized, and benign lesions can be completely resected for cure 
with recurrence being rare (excluding syndromic neurofibromas that may be as 
high as 15%) [7, 9, 39]. However, surgical resection of diffuse, plexiform, and 
soft tissue-type neurofibromas should rarely be undertaken and only in select 
cases with clear surgical goals due to the high associated morbidity [9, 39]. 
Compared to schwannomas and depending on the specific subtype, neurofi-
broma resection is often more challenging (greater nerve fascicle integration) 
and is associated with a higher risk of postoperative nerve injury [40]. To help 
mitigate this, intraoperative monitoring has been shown to be a useful adjunct to 
discern functional and non-functional tissue [15]. Postoperative motor deficits 
after neurofibroma resection have been reported in approximately 6% of cases 
with the incidence of new postoperative deficit being previously shown to be 
comparable to that of schwannomas. However, neurofibroma resection involved 
more extensive nerve dissection with a higher incidence of subtotal resection. 
Furthermore, in their study, Levi et al. showed that 85% of patients had stable or 
improved function after resection [15]. In keeping with this, in a separate study, 
all patients with a preoperative motor deficit remained stable or improved after 
neurofibroma resection [39].
For suspected or established cases of MPNSTs, systemic staging investigations 
should be done to help establish management goals. Cases should be referred to 
a tertiary care center experienced in MPNST patient management with an estab-
lished multidisciplinary tumor board. In the setting of metastases, a palliative 
surgical resection with chemotherapy and/or radiotherapy is usually undertaken. 
In contrast, en-bloc surgical resection (with or without pre- and/or postoperative 
chemo-/radiotherapy) is the mainstay of treatment for localized tumors without 
evidence of metastases. Negative tissue margins are the resection goal when feasible 
and represent an important prognostic factor in the setting of high-grade MPNST 
[41]. However, in the case of low-grade MPNSTs and atypical neurofibromas, the 
effect of a negative surgical margin is still unclear and must be weighed against the 
associated morbidity in achieving this [42]. In general, functional reconstruction of 
surrounding structures is a secondary consideration and, when possible, should not 
impede surgical resection [9, 21].
In the setting of large tumors for resection, adjunctive preoperative radiation 
therapy may be used when en-bloc resection is difficult due to size and surround-
ing structures. This too, however, must be weighed against the increased difficulty 
associated with operating in an irradiated field. Furthermore, a survival benefit 
for its use has not been established [8]. In contrast, postoperative radiotherapy 
for MPNSTs is often required, especially for high-grade tumors or subtotal tumor 
resection. Again however, although it may limit local recurrence [21, 43], its effect 
on OAS is more ambiguous. Proton therapy has also been suggested as a potential 
adjunct [9]. More recent studies have suggested increased local control rates, though 
an effect on OAS remains to be seen [39]. More controversial than radiotherapy is 
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the role of chemotherapy for MPNSTs. MPNSTs typically only partially respond in a 
small subset of patients with no significant OAS benefit. More specifically, ifos-
famide and doxorubicin have been previously used in metastatic disease or to reduce 
tumor size prior to surgery [9, 44]. Regardless of postoperative regimen, long-term, 
close postoperative clinical and radiological follow-up of patients with MPNSTs is 
essential due to the high rate of recurrence of these tumors [9, 39].
MPNSTs have a dismal overall prognosis [45]. Incidence of local recur-
rence can be as high as 65%. Previous studies have reported 5-year disease-free 
survival rates varying between 30 and 60%, and a 5-year OAS rate of approxi-
mately 30% [9, 10, 28, 39]. Poor prognostic factors have been previously shown 
to include tumor size ≥5 cm, truncal/midline location, subtotal resection (for 
high-grade tumors especially and its role in low-grade lesions being less cer-
tain), high-grade and advanced stage tumors, previous radiation, and NF1-
associated tumors [28, 39, 41, 42].
2.7 Case presentation
A 42-year-old man with a history of NF1 presented with right buttock and 
lower extremity pain, accompanied by paresthesias. MR neurogram revealed a 
right sciatic nerve PNST (neurofibroma) at the sciatic notch and a left hemi-pelvis 
PNST arising from the inferior aspect of the left L5 nerve root (Figure 1). A poste-
rior, transgluteal approach was used to successfully remove the right-sided sciatic 
neurofibroma with intraoperative neurophysiological monitoring. Clinical and 
radiological follow-up were planned for the left-sided lesion after treatment of his 
symptomatic lesion. The patient’s pain and paresthesias resolved postoperatively, 
and he recovered without complication.
Figure 1. 
(A) T2 weighted MRI, coronal section; (B) T2 weighted MRI, axial section; (C) T2 weighted MRI, coronal 
section; and (D) T2 weighted MRI, axial section. Large round nerve sheath tumor of the sciatic nerve at the 
sciatic notch (panels A and B), and large left nerve sheath tumor in the left hemi-pelvis, arising from the 
inferior aspect of the left L5 nerve root (panels C and D).
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3. Neurofibromatosis type 2
3.1 Background
In keeping with NF1, NF2 is an AD neurocutaneous disease characterized by 
a propensity to form craniospinal lesions, most commonly vestibular schwan-
nomas [30, 31]. Its incidence has been reported to range from 1:30,000 to 40,000 
individuals. Also in keeping with NF1, NF2 results from a loss of function 
mutation of a tumor suppressor gene located on chromosome 22q12.2. This gene 
encodes a protein called merlin (or schwannomin). Merlin is a member of the 
ezrin, radixin, meosin (ERM) protein family whose function includes anchoring 
the cytoskeleton to the plasma membrane, interacting with cytosolic elements, 
and contact-dependent inhibition of proliferation [30, 31, 46, 47]. Through Ras 
modulation, merlin also acts as a negative regulator of several other transduction 
pathways [47].
Epidemiologically, NF2 shows no gender, nor racial predilection, and approxi-
mately half of NF2 patients acquire a de novo mutation resulting in its expression. 
Furthermore, 59% of the latter acquire mutation in a somatic mosaic pattern 
(as opposed to germ line mutation), which portends a better prognosis [47, 48]. 
Penetrance for the disease approaches 100% in familial patients; however, it may 
vary in the offspring of mosaic patients [48, 49]. Similar to NF1, specific phenotypic 
expression and its severity can be dictated by different genotypes; several pheno-
types have been described. More specifically, Wishart, Gardner, and congenital 
types have been described. The Wishart phenotype has the highest incidence and 
typically displays more rapid disease progression with earlier onset. In contrast, the 
Gardner subtype is a less severe form of NF2 with onset later into adulthood [50, 51]. 
A third type, congenital NF2, is associated with dermal plaques in atypical locations, 
such as the face and hands [51]. The latter phenotype of NF2 tends to be more severe 
and heterogeneous [46].
3.2 Schwannoma histopathology and subtypes
As their name implies, schwannomas are BPNSTs that develop from Schwann 
cells and present as well-circumscribed, encapsulated lesions. They are the most 
common BPNSTs of adulthood and tend to displace rather than infiltrate nerves 
(fascicles being grossly visible to the exterior of the tumor). Lobular in shape with a 
rubbery external consistency, these tumors may include cystic cavities, foamy nests, 
fibrotic and mineralized components, in addition to a hemorrhagic core [4, 52]. 
Microscopically, two distinct architectures exist: Antoni A and B. Antoni A areas 
consist of higher cellularity with spindle-like cells and elongated nuclei arranged in 
palisades (Verocay bodies). Antoni B tumor areas have a lower cellularity with loose 
reticular fibers in a myxoid background.
Similar to plexiform neurofibromas, plexiform schwannomas are Schwann 
cell tumors that encompass multiple nerve fascicles coming together into a 
multi-nodular, loculated growth around the nerves. This subtype will frequently 
affect the cervical region, brachial plexus, and lumbosacral plexus [48]. They 
can be grossly distinguished from plexiform neurofibromas, however, by a less 
diffuse distribution and their typically affecting a single nerve or nerve trunk 
[35]. Though not pathognomonic for NF2, they occur more frequently in this 
population.
Dermal or cutaneous schwannomas are masses specific to NF2 patients. They 
do not occur sporadically or in association with SWNTS and present as a distinct 
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en-plaque-like mass. These lesions originate from neoplastic Schwann cells that 
expand the parent nerve and infiltrate adjacent structures including the dermis, 
hair follicles, and sebaceous glands [50].
Nodular are the most common type of schwannoma. They can occur in a myriad 
of locations and from a plethora of nerves—cranial, spinal, and peripheral [50]. 
These tumors tend to grow on flexor surfaces more than the extensor surface of 
extremities, as well as the head, neck, and upper extremities more than the lower. 
As mentioned, they will typically grow and displace nerve fascicles to the outside 
of their capsule. The growth rate of these sporadic growing schwannomas can vary 
substantially; however, it has been reported to be approximately 1–2 mm/year and 
3 mm/year in those tumors demonstrating early growth at follow-up (although rates 
as high as 17 mm/year have been reported) [53].
3.3 Clinical presentation
NF2 patients usually present in the second to third decade of life (mean 
age 27-year-old with a mean time to diagnosis from symptom onset of 7 years) 
[47]. Diagnosis of NF2 is dependent on fulfilling the Manchester clinical cri-
teria (although this may not be the most appropriate diagnostic scheme in, for 
example, congenital and childhood NF2) [46, 48, 54]. NF2 is characterized 
by the presence of several different CNS tumors, most notably the growth of 
bilateral vestibular schwannomas (affecting 90–95% of patients and typically 
presenting with sensorineural hearing loss, tinnitus, and balance difficulties). 
Other commonly occurring lesions include spinal tumors (60–90% of patients), 
meningiomas (50% of patients), gliomas, ependymomas, astrocytomas, posterior 
subcapsular cataracts, retinal hamartomas, and cerebral calcifications [30, 31, 46, 
54, 55]. Congenital and childhood NF2 usually present differently than the typical 
adult onset presentation of vestibular schwannomas (least likely to occur); these 
patients are more likely to present with a spinal cord tumor, peripheral nerve, or 
skin lesion [55]. Approximately 70% of NF2 patients will also present with cuta-
neous and peripheral manifestations of the disease including hyperpigmented 
plaques, subcutaneous nodules, and neurofibromas (although nodular schwan-
nomas are still more common and tend to occur around peripheral nerves) [46]. 
Furthermore, although more common in NF1, up to 50% of NF2 patients may also 
develop café-au-lait spots (typically smaller, less numerous, and paler with more 
irregular margins) [46, 56].
When they do occur, neurofibromas tend to have a hybrid neurofibroma-
schwannoma histopathology [50, 52]. Furthermore, compared to SWNTS patients, 
NF2 schwannomas are more likely to present in childhood/young adulthood and 
result in neurologic deficit rather than pain [50]. These tumors have a predilec-
tion for sensory nerves with an average rate of growth of approximately 1–2 mm/
year (though different lesions within the same individual may grow at different 
rates) [47, 57]. Finally, non-vestibular cranial nerves (e.g., cranial nerves 5, 7, 
9, 10) affect about 50% of NF2 patients [50], and malignant transformation of 
NF2 (vestibular) schwannomas has not been demonstrated to be higher than the 
general population in non-irradiated cases [58]. However, aggressive retroperito-
neal tumors and spinal SMARCB1-deficient MPNSTs do occur at an increased rate, 
and malignant transformation has been suggested to be 10 times more likely after 
radiation treatment [47, 59].
NF2 can also present localized to a particular part of the body or nervous system 
as seen in mosaic, or segmental forms of the disease. Segmental NF2 presents as a 
less severe form of the disease [59] and occurs more frequently in sporadic NF2 cases 
Neurofibromatosis - Current Trends and Future Directions
10
(20–30% of patients carrying a de novo somatic mosaic mutation) vs. syndromic 
[30, 31]. This form of NF2 may also clinically overlap with sporadic SWNTS [51].
Akin to NF1, NF2 patients may also experience peripheral neuropathy (66% 
of NF2 patients) [60]. This typically presents as a mixed sensory-motor axonal 
peripheral mononeuropathy (not due to mass lesion) in children causing foot 
drop or wasting of thenar and hypothenar eminences, and severe progressive 
polyneuropathy in adults [50, 52, 56]. The pathogenesis might involve nerve 
compression by Schwann cell tumorlets or aberrant non-neoplastic Schwann 
cells [48, 50].
3.4 Imaging
MRI represents the most precise means of diagnosis [59]. On T1-weighted 
imaging, NF2-associated schwannomas appear isointense to muscle with a 
possible split-fat sign. On T2-weighted imaging, target-sign, fascicular-sign, 
and/or intratumoral cysts may be present resulting in heterogeneous high signal 
intensity. Enhancement is variable [52]. Internal calcification, hemorrhage, 
and cyst formation are more commonly seen in schwannomas than neurofibro-
mas. Whole-body MRI can be used to assess tumor burden and distribution of 
schwannomas for the purposes of diagnosis, surveillance, and optimal treat-
ment timing [46, 52]. MRI adjunct sequences such as diffusion tensor imaging 
(DTI) may help in distinguishing schwannomas by demonstrating the eccentric 
location of the lesion relative to nerve fibers. Tractography can also be useful in 
preoperative planning by demonstrating the nerve fiber displacement pattern 
around the lesion. The ADC value can be quite variable in NF2 lesions with a 
minimum ADC range of 0.8–2.7 × 10−3 mm2/s (values <0.9 are concerning for 
malignancy).
Unlike in NF1 patients, FDG-PET imaging holds little value in the management 
of NF2 patients and schwannomas.
On US, solitary schwannomas appear as hypoechoic, homogeneous lesions with 
distinct borders, an oval shape, and the absence of vascularization. Normal fascicu-
lar displacement may be seen, as can focal nerve enlargements, hypoechoic cysts 
and fascicles, and hyperechoic calcifications [35, 60].
3.5 Management and outcome
In a similar fashion to neurofibromas, schwannomas (whether sporadic 
or syndromic) are typically slow growing and may not lead to neurological 
dysfunction for many years [57]. Surgical resection of a schwannoma may be 
indicated in cases of neurological deficit referable to the lesion (pain, numbness, 
paresthesias, and weakness), growth demonstrated on serial imaging, question-
able diagnosis or malignancy, and cosmesis. Surgical treatment in the way of 
gross total resection is often curative and successful at alleviating presenting 
symptoms. Rarely does it lead to neurologic deficit, need for parent nerve resec-
tion, or tumor recurrence (depending on the location and size, notably vestibular 
schwannomas) [15, 51]. However, not all lesions are suitable for complete surgi-
cal resection (again depending on location, accessibility, and neural involve-
ment, among others) in which case the goal should be maximal safe resection 
and functional preservation [61]. Schwannomas in the context of NF2 are more 
likely to result in subtotal resection than sporadic lesions (former tends to 
include more nerve fascicles and be more adherent to adjacent structures) [50]. 
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Moreover, dermal tumors are not usually resected, unless they are disfiguring or 
are functionally burdensome.
Careful consideration should be given to the use of radiotherapy in NF2 patients 
due to the risk of inducing or accelerating the progression of tumors, especially 
in pediatric patients [57]. However, stereotactic radiosurgery has been success-
fully used in treating vestibular schwannomas of NF2 patients and resulted in 
a higher rate of facial nerve preservation [62]. Currently, little guidance in the 
literature exists for the use of chemotherapy or radiation in the treatment of NF2-
associated PNSTs.
In the context of NF2, age of onset is one of the most important determinants 
of disease severity [46]. The clinical course of the disease is highly variable, but 
NF2 patients suffer from a shortened life-expectancy by about 10 years [61]. The 
twenty-year OAS rate has been reported to be as low as 38% [51]. Tumor burden, 
perioperative complications, and malignancy have been cited as the most common 
causes of mortality in this group of patients [47, 50, 51].
3.6 Case presentation
A 45-year-old woman with NF2 presented with a palpable mass in her popliteal 
fossa and pain in the area radiating down her calf into the sole of her foot. MR 
neurogram showed a PNST arising from the left tibial nerve, ADC values consis-
tent with a benign tumor, and tractography showing splaying of nerve fascicles 
eccentric to the tumor (as shown in Figure 2). Operative resection of the tumor was 
completed with neurophysiological monitoring being used to identify silent tumor 
areas and viable nerve fascicles.
Figure 2. 
(A) and (B) T2 weighted MRI, sagittal view. (C) T2 weighted MRI, axial view. (D) Diffusion tensor imaging 
with tractography reconstruction. Large, round, and well-circumscribed peripheral nerve sheath tumor 
(schwannoma) arising from the left tibial nerve in the popliteal fossa. Tractography demonstrated intact nerve 
fascicles being splayed eccentrically posterior and medial to the tumor.
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4. Schwannomatosis
4.1 Background
Schwannomatosis is another neurocutaneous disease characterized by the 
development of multiple BPNSTs, namely schwannomas (in the absence of NF1/2 
history). The disease typically has a later onset (second to fourth decade), and 
some reports suggest a female preponderance [63, 64]. The reported incidence for 
SWNTS is quite variable; however, many approximate it to be 1:40,000–1:70,000 
with a prevalence of 1:70,000–1:160,000 [57]. In contrast to NF1 and NF2, it almost 
exclusively affects the PNS [31] and can be inherited in a sporadic or AD fashion 
due to germ line mutation. However, sporadic SWNTS is significantly more com-
mon (under 20% of patients having an affected parent), [64] and familial cases 
generally present at a slightly younger age [63].
As the most common adult PNST, most schwannomas present in the third to 
sixth decade of life [3]. Many are found incidentally, and due to their slow growing 
nature, many are quite sizeable before the onset of symptoms (typically presenting 
with pain and not neurological deficit). The occurrence of multiple schwannomas 
in one patient should raise suspicion for SWNTS. These tumors can occur in several 
different locations, including in the paraspinal and retroperitoneal areas, as well 
as brachial plexus [65]. SWNTS can also lead to the growth of other tumor types 
such as meningiomas. This, in addition to the presence of vestibular schwannomas 
in SWNTS, can result in considerable overlap and misdiagnosis of SWNTS as NF2 
(especially as mosaic NF2) [57].
Two gene mutations related to chromosome 22q have been identified as resulting 
in SWNTS—LZTR1 and SMARCB1. Patients with the LZTR1-associated mutation 
are more likely be affected by a vestibular schwannoma and acquire the sporadic 
form of SWNTS. Malignant transformation in patients with SWNTS is rare, but 
does occur. However, mutations in the SMARCB1, LZTR1, and the CoQ6 genes have 
been implicated in the pathogenesis of SWNTS both in the familial and sporadic 
cases. Many, as of yet, unknown mutations may also be implicated considering 
that SMARCB1 and LZTR1 genes were found in only 10% of sporadic and 60% of 
familial SWNTS cases [66]. Furthermore, in sporadic cases, 55% of the patients did 
not have their pathogenic variant found, while this was the case in only 31% of the 
familial cases [40, 57].
4.2 Schwannomatosis histopathology and subtypes
Schwannomas are well-circumscribed, encapsulated, intraneural lesions that 
most frequently arise from a single fascicle and tend to grow extrinsic to their 
parent nerve. This results in surrounding fascicles being splayed to the tumor 
periphery (is in contrast to neurofibromas) [3, 39]. It is not uncommon for multiple 
schwannomas to occur along the same nerve [67]. Although the majority of lesions 
are solitary (96%), plexiform lesions do occur (4%) [68].
Morphologically, SWNTS-associated schwannomas are similar to lesions 
occurring in NF2 or sporadic cases. Namely, Verocay bodies, Antoni A/B archi-
tecture, encapsulation, and hyalinized vessels are present. In addition to the 
above anatomical description of schwannomas, there are also several different 
histological categories as well. These include conventional or ancient type (com-
monly displaying degenerative changes such as calcification, cystic change, 
necrosis and hemorrhage, though usually still follow an indolent course), cellular 
type (predominantly made up of Antoni A areas, hypercellular with occasional 
mitotic figures and nuclear atypia, and although may have a higher recurrence 
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rate, still considered benign), melanotic type (comprised of non-psammomatous 
and psammomatous types with melanin hyperpigmentation and associated 
with Carney’s syndrome; may be or become malignant), and plexiform type (as 
previously described). Furthermore, mixed or hybrid neurofibroma-schwannoma 
histopathologic tumor appearance is more frequent in SWNTS than in the other 
tumor predisposition disorders [4]. Furthermore, although in the absence of 
radiation exposure schwannomas are not necessarily more prone to malignant 
degeneration in the setting of NF2, this may not be the case for SWNTS. In a 
previous study, MPNSTs were noted to occur in 3/181 cases of SWNTS associated 
with SMARCB1 mutations [69].
4.3 Clinical presentation
The clinical presentation of SWNTS is more non-specific than that of the 
other familial tumor syndromes discussed [57]. This is likely due to the fact that 
compared to NF1/2, SWNTS will present with more subtle findings related to 
slow tumor growth (as opposed to cutaneous manifestations). The most com-
mon presenting complaint is pain (focal or diffuse) without neurological deficit, 
and the presence of a large mass [3, 57, 63, 70]. One previous study found that 
approximately 60% of patients will have numbness and 30% will have paresthesias 
at presentation. However, motor deficits are rare [39]. Weakness and atrophy are 
typically late findings, [64] though they have been found in 12.8% of tumors in one 
study [39]. It should also be noted that due to mosaicism, SWNTS can also present 
as a localized, segmental process, which is the case in about 30% of patients [47, 68].
Compared to NF2 patients, SWNTS demonstrates a higher incidence of periph-
eral nerve and spinal lesions [57]. Schwannomas will affect peripheral nerves most 
commonly (95%), followed by spinal nerves (75%) with the lumbar spine most 
often affected [64]. Moreover, cranial nerves may be affected (trigeminal being 
the most common), though much less commonly [64]. Patients with SWNTS have 
a significantly lower incidence of meningiomas, ependymomas, trigeminal, and 
vestibular schwannomas (unilateral still being in keeping with an SWNTS diag-
nosis) than do patients diagnosed with NF2 [57]. Meningiomas in association with 
schwannomas do occur, as do isolated cutaneous neurofibromas; however, patients 
presenting with schwannomas tend to be older than those presenting with neurofi-
bromas for NF1/2 [30, 31]. Diagnosis of SWNTS (and differentiating SWNTS from 
NF1/2) is predicated on clinical criteria or combined clinical-molecular criteria 
recently proposed by Kehrer-Sawatzki et al. [71]. However, biopsy to obtain a 
definitive diagnosis of schwannoma is no longer recommended given the associated 
risk of neurological injury and increased risk of postoperative neurological deficit 
after resection [15].
Similar to NF1 and NF2, SWNTS patients can also present with neuropathy 
(outside of that explained by obvious tumor compression). Patients may suffer 
from a tumor-independent, intrinsic nerve deficit presenting as a mononeuropathy 
or polyneuropathy [4]. After investigations are completed, the majority of SWNTS 
patients presenting with neuropathic pain do not end up having a causative tumor 
identified. Furthermore, although neurophysiological investigations are often 
normal in these patients, high-resolution MR neurography has previously demon-
strated intrafascicular microlesions. As such, the notion of not finding a causative 
tumor may simply be an issue of commonly used investigations not being sensitive 
enough to detect them (tumorlets as seen in NF1/2 being the culprit). Alternatively, 
an abnormally and diffusely thickened nerve may be to blame [4, 68]. Whether or 
not these findings are the cause of the pain, and not merely correlative, is another 
issue. However, SMARCB1-deficient Schwann cells have also been shown to release 
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factors that stimulate nociceptive DRG neurons [4, 61, 68]. These are only a few of 
the ongoing research areas of SWNTS, as well as NF1/2, being actively pursued.
4.4 Imaging
Imaging characteristics for lesions in patients with SWNTS are similar to 
those found in solitary lesions previously described. On T1-weighted MRI, 
lesions appear homogeneously hypo- to isointense to muscle. Postcontrast 
T1 imaging typically demonstrates heterogeneous enhancement, while fluid-
sensitive sequences demonstrate heterogeneous hyperintensity [68]. High-signal 
intensity on T2 is also usually seen. The use of whole-body MRI is an efficient 
way in SWNTS patients to evaluate and screen the overall tumor burden, as well 
as survey for tumor growth or change. With respect to other hallmark features, 
a target-sign (20%), split-fat sign (96%), tail-sign (36%), and tumor-nerve 
eccentricity (33%) may all be seen [68].
Although metabolic imaging is useful for malignancy surveillance in neurofibro-
mas, its utility in schwannomas is limited due to the high FDG-avidity of schwan-
nomas, which can consequently mimic malignancy [68, 70].
4.5 Management and outcome
Management for these tumors is similar in nature to that of schwannomas 
found in other neurocutaneous syndromes. Surgical indications have been outlined 
above in the NF1/2 sections. Previous studies have demonstrated good outcomes 
with surgical resection with very low risk of recurrence in the setting of gross total 
resection. Tumor resection with functional nerve/nerve fascicle preservation is the 
surgical goal when possible [39, 63]. Surgical removal is typically associated with 
little to no injury of the parent nerve, in contrast to neurofibromas in which there 
is a higher associated risk [3, 39]. Resection is carefully performed with removal 
of tumor capsule unless it is firmly adherent to the surrounding nerve. In the case 
of the latter, it is left in place. Gross total resection has been previously reported as 
being achievable in close to 80% of cases peripherally located (versus plexus) [39]. 
Recurrence of schwannomas after surgical removal is rare; however, it is greatest 
in cases of subtotal resection and in patients diagnosed with SWNTS (recurrence 
rate of 14.3% with an odds ratio of 4.29) [3, 39]. A revised diagnosis of NF2 is also 
associated with a worse overall prognosis. In comparison, SWNTS patients have a 
higher OAS than NF2 patients (mean age of 76.9 vs. 66.2 years, respectively) [18, 
57, 67]. The most frequent postoperative complication is paresthesia; however, 
motor (5.2%) and sensory (7.5%) deficits can also occur, in addition to neuropathic 
pain despite appropriate surgical and nonsurgical management (often unrelated to 
tumor size) [3, 39, 47, 72].
No medical treatments are currently available for patients with SWNTS [3]. 
However, as for all PNST patients presenting with significant neuropathic pain, 
neuromodulatory medication such as amitriptyline, pregabalin, and gabapentin 
should be considered [4]. The use of radiation therapy for treatment of SWNTS-
related lesions has not been rigorously assessed and considered only in cases of 
malignancy or clinically debilitating/unresectable lesions due to the risk of malig-
nant transformation [47].
4.6 Case presentation
A 42-year-old man with a personal and family history of multiple, recurrent 
schwannomas presented with a palpable tumor arising from the dorsal aspect of the 
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right ulnar nerve (progressively enlarging since childhood). The mass was located 
near the right medial epicondyle (as shown on his MRI depicted in Figure 3), and 
associated with painful paresthesias upon palpation in an ulnar distribution. On 
exam, he had weakness and atrophy of his dorsal and palmar interossei. Operative 
resection was completed using neurophysiological monitoring to identify silent 
tumor areas for its safe removal along with the fascicle of origin while preserv-
ing the parent ulnar nerve. At last follow-up, the patient’s sensory symptoms had 
resolved, and he had regained some strength; however, his atrophy persisted.
5. Conclusion
Since the initial description of neurofibromatosis (and subsequently schwan-
nomatosis), our understanding of the molecular pathogenesis underlying these 
neurocutaneous disorders, their clinical manifestations, and respective natural 
histories has greatly evolved. Technological advancements in areas such as 
genomic sequencing and radiological imaging have improved both the diagnostic 
and therapeutic aspects of these patients’ care. Despite these advancements, 
however, substantial work remains in order to fully comprehend the depth of 
these diseases. It is only through the continued collaboration of research groups 
and consortiums that these obscure areas will come to light and translate into 
improved patient care.
Figure 3. 
(A) T1 weighted MRI, coronal section. (B) T2 weighted MRI, coronal section. (C) T1 weighted MRI, axial 
section. (D) T2 weighted MRI, axial section. Oval, homogeneously enhancing, mass in the dorsal right forearm 
medial to the triceps arising from the right ulnar nerve.
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